Navigation Links
Cord Blood America Reduces "Afford-A-Cord" Program Charges; New Buyers Anticipated
Date:5/12/2011

LAS VEGAS, May 12, 2011 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC BB: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it is reducing the monthly payment in its unique "Afford-A-Cord" storage program from $29 a month to $19.

Afford-A-Cord reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service.  The Afford-A-Cord program is offered as an additional payment option to the Company's long standing traditional payment programs.  It accounted for four percent of the Company's revenues in the most recent fiscal year.  

"The data tells the story.  It was four percent of our revenues, and without a doubt, these families would otherwise not have bought cord blood storage at all.  The Afford-A-Cord program is strictly designed to bring in new buyers that historically could not afford to store stem cells.  By reducing the monthly fee even further, our expectation is that this program will become an even greater portion of our business portfolio," said Matthew Schissler, Cord Blood America co-founder and CEO.  

"Parents and grandparents who realize the importance of storing a baby's umbilical cord blood stem cells, but who are strapped financially, still should have the opportunity to participate in this potentially live saving program," Mr. Schissler said.  "No other company offers such a low entry point, one that will allow a greater number of families to store their child's stem cells and, with the lowering of the monthly fee, we hope to provide this service to more families whose financial situations are difficult in the current economy."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAID) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of diseases, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

   CONTACT:
   Paul Knopick
   E & E Communications
   949/707-5365
   pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America Announces BioCells, Inc., Which it Acquired in 2010, is Opening Office in Miami, Florida and 5 New Offices in Argentina Soon
2. Cord Blood America Announces Reverse Stock Split Takes Effect Monday, May 9, 2011
3. ThermoGenesis Announces China Customer Implements Cord Blood Products
4. Cord Blood America: Shareholders Approve Common Stock Reverse Split
5. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression to be Presented at the American Psychiatric Association Annual Meeting
6. Cord Blood America: Court Grants Motion to Dismiss at Lawsuit Aimed at Blocking Acquisition
7. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
8. New England Cord Blood Bank: Umbilical Cord Tissue Banking
9. China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego
10. Cord Blood America Announces Affiliate Program to Educate on Value of Umbilical Cord Blood Stem Cell Storage
11. New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
Breaking Biology News(10 mins):